报价延迟最少15分钟:2026/04/26 08:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.27 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.33/-0.56
|
|
企业价值
109.11M
|
| 资产负债 |
|
每股账面净值
1.28
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
90.50M
|
|
每股收益
1.53
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic andeither do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA. |
